PMID- 23956349
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20151119
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 10
DP  - 2013 Oct
TI  - Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in 
      multiple endocrine neoplasia type 1 patients.
PG  - 4143-51
LID - 10.1210/jc.2013-1800 [doi]
AB  - CONTEXT: The assessment of tumor markers for diagnosing pancreatic neuroendocrine 
      tumors (pNET) in multiple endocrine neoplasia type 1 (MEN1) patients is advised 
      in the current guidelines but has never been validated for this purpose. 
      OBJECTIVE: The objective of the study was to assess the diagnostic accuracy of 
      chromogranin A (CgA), pancreatic polypeptide (PP), and glucagon for pNET in MEN1. 
      DESIGN: This was a diagnostic study. SETTING: The study was conducted at Dutch 
      university medical centers from 2008 to 2011, representing 90% of the total Dutch 
      MEN1 population. PATIENTS AND METHODS: Patients for whom data on tumor markers in 
      combination with the reference standard (ie, radiological imaging) were available 
      between 2008 and 2011 were included. The reference standard for the presence of 
      pNET was pathology or detection on magnetic resonance imaging, computed 
      tomography, or endoscopic ultrasound confirmed on subsequent imaging, 
      irrespective of modality at follow-up. MAIN OUTCOME MEASURES: The area under the 
      receiver-operating characteristic curve (AUC), positive predictive value, 
      negative predictive value, positive likelihood ratio, negative likelihood ratio, 
      sensitivity, and specificity were calculated for each marker. RESULTS: For the 
      analysis of PP, CgA, and glucagon, 73, 81, and 94 patients were available, 
      respectively. The AUC for CgA was 0.48 [95% confidence interval (CI) 0.35-0.61] 
      with a sensitivity 0.33 and a specificity 0.73; the AUC for glucagon was 0.58 
      (95% CI 0.46-0.70) with a sensitivity 0.43 and a specificity 0.73; and the AUC 
      for PP was 0.64 (95% CI 0.50-0.77) with a sensitivity 0.36 and a specificity 
      0.74. Age, imaging modality, tumor size, and number did not influence the 
      outcomes. CONCLUSION: The diagnostic accuracy of the tumor markers CgA, PP, and 
      glucagon for pNET in MEN1 is low.
FAU - de Laat, Joanne M
AU  - de Laat JM
AD  - MD, PhD, Department of Internal Medicine, L00.408, University Medical Center 
      Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. G.D.Valk@umcutrecht.nl.
FAU - Pieterman, Carolina R C
AU  - Pieterman CR
FAU - Weijmans, Maaike
AU  - Weijmans M
FAU - Hermus, Ad R
AU  - Hermus AR
FAU - Dekkers, Olaf M
AU  - Dekkers OM
FAU - de Herder, Wouter W
AU  - de Herder WW
FAU - van der Horst-Schrivers, Anouk N A
AU  - van der Horst-Schrivers AN
FAU - Drent, Madeleine L
AU  - Drent ML
FAU - Bisschop, Peter H
AU  - Bisschop PH
FAU - Havekes, Bas
AU  - Havekes B
FAU - Vriens, Menno R
AU  - Vriens MR
FAU - Valk, Gerlof D
AU  - Valk GD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130816
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chromogranin A)
RN  - 59763-91-6 (Pancreatic Polypeptide)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Chromogranin A/blood
MH  - Female
MH  - Glucagon/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*blood
MH  - Neuroendocrine Tumors/blood/*diagnosis
MH  - Pancreatic Neoplasms/blood/*diagnosis
MH  - Pancreatic Polypeptide/blood
EDAT- 2013/08/21 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/08/20 06:00
PHST- 2013/08/20 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - jc.2013-1800 [pii]
AID - 10.1210/jc.2013-1800 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Oct;98(10):4143-51. doi: 10.1210/jc.2013-1800. Epub 
      2013 Aug 16.